1. P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019) Authors: Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; Ye, Y; Cho, T; Moran, S; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-086EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment. (2nd July 2019) Authors: Su, M; Chen, L; Hitre, E; Lee, W; Bai, L; Papai, Z; Kang, S; Dvorkin, M; Lee, M; Ludovic, E; Choi, H; Oh, S; Bodoky, G; Artru, P; Hwang, J; Bazin, I; Bosc, F; Bachet, J; Horváth, Z; Chang, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. (23rd October 2018) Authors: Kümmel, S; Tondini, C A; Abraham, J; Nowecki, Z I; Itrych, B; Hitre, E; Karaszewska, B; Juarez, A; Morales-Vásquez, F; Pérez García, J M; Cardona-Huerta, S; Heinzmann, D; He, J; Duc, A N; Crepelle-Fléchais, A; Martín, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗